Endogenous Mechanisms Regulating TNF and IL-1 during Sepsis

[1]  W. Sibbald,et al.  Clinical Trials for the Treatment of Sepsis , 2011, Update in Intensive Care and Emergency Medicine.

[2]  T. van der Poll,et al.  Regulation of interleukin 10 release by tumor necrosis factor in humans and chimpanzees , 1994, The Journal of experimental medicine.

[3]  S. Dower,et al.  The two interleukin-1 receptors play different roles in IL-1 actions. , 1994, Clinical immunology and immunopathology.

[4]  R. F. Johnston,et al.  Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial , 1994 .

[5]  T. van der Poll,et al.  Noradrenaline inhibits lipopolysaccharide-induced tumor necrosis factor and interleukin 6 production in human whole blood , 1994, Infection and immunity.

[6]  P. Vandenabeele,et al.  Interleukin‐10 controls interferon‐γ and tumor necrosis factor production during experimental endotoxemia , 1994, European journal of immunology.

[7]  W. Buurman,et al.  Slow release of soluble TNF receptors by monocytes in vitro. , 1994, Journal of immunology.

[8]  T. van der Poll,et al.  Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees , 1994, The Journal of experimental medicine.

[9]  J. Devière,et al.  Interleukin-10 production during septicaemia , 1994, The Lancet.

[10]  T. van der Poll,et al.  Tumor necrosis factor is involved in the appearance of interleukin-1 receptor antagonist in endotoxemia. , 1994, The Journal of infectious diseases.

[11]  T. van der Poll,et al.  Platelet-activating factor antagonist TCV-309 attenuates the induction of the cytokine network in experimental endotoxemia in chimpanzees. , 1994, Journal of immunology.

[12]  G. Monastra,et al.  Beta-adrenergic receptors mediate in vivo the adrenaline inhibition of lipopolysaccharide-induced tumor necrosis factor release. , 1993, Immunology letters.

[13]  I. Olsson,et al.  Interleukin-1 beta induces interleukin-1 receptor antagonist and tumor necrosis factor binding protein in humans. , 1993, Cancer research.

[14]  S. Calvano,et al.  Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. , 1993, Journal of immunology.

[15]  C. Dinarello,et al.  Elaboration of interleukin 1-receptor antagonist is not attenuated by glucocorticoids after endotoxemia. , 1993, Archives of surgery.

[16]  W. Fiers,et al.  Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia , 1993, The Journal of experimental medicine.

[17]  C. Libert,et al.  Limited involvement of interleukin‐6 in the pathogenesis of lethal septic shock as revealed by the effect of monoclonal antibodies against interleukin‐6 or its receptor in various murine models , 1992, European journal of immunology.

[18]  J. Mier,et al.  Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. , 1992, Cytokine.

[19]  C. Hunter,et al.  Regulation of tumor necrosis factor production by adrenaline and beta-adrenergic agonists. , 1992, Journal of immunology.

[20]  L. Moldawer,et al.  Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[21]  L. Moldawer,et al.  Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease. , 1992, Blood.

[22]  D. Remick,et al.  Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. , 1992, The Journal of clinical investigation.

[23]  P. Abbet,et al.  Cytokine production after intravenous or peritoneal gram-negative bacterial challenge in mice. Comparative protective efficacy of antibodies to tumor necrosis factor-alpha and to lipopolysaccharide. , 1992, Journal of immunology.

[24]  D. Wallach,et al.  Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors , 1992, The Journal of experimental medicine.

[25]  H. Büller,et al.  Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans , 1991 .

[26]  F. Cozzolino,et al.  IL-1 receptor antagonist production by B and T lymphocytes , 1991 .

[27]  Marcel,et al.  Fibrinolytic response to tumor necrosis factor in healthy subjects , 1991, The Journal of experimental medicine.

[28]  C. Dinarello.  Interleukin-1 and interleukin-1 antagonism. , 1991, Blood.

[29]  Robert C. Thompson,et al.  Interleukin-1 receptor antagonist reduces mortality from endotoxin shock , 1990, Nature.

[30]  B. Echtenacher,et al.  Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. , 1990, Journal of immunology.

[31]  T. van der Poll,et al.  Activation of coagulation after administration of tumor necrosis factor to normal subjects. , 1990, The New England journal of medicine.

[32]  A C Allison,et al.  The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans. , 1990, The Journal of clinical investigation.

[33]  K. Tracey,et al.  Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia , 1989, The Journal of experimental medicine.

[34]  J. Norton,et al.  Reversal of the toxic effects of cachectin by concurrent insulin administration. , 1989, The American journal of physiology.

[35]  E. Girardin,et al.  Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. , 1988, The New England journal of medicine.

[36]  T. Ikejima,et al.  Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. , 1988, The Journal of clinical investigation.

[37]  K. Tracey,et al.  Cytokine appearance in human endotoxemia and primate bacteremia. , 1988, Surgery, gynecology & obstetrics.

[38]  J. D. Albert,et al.  Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. , 1987, Surgery, gynecology & obstetrics.

[39]  A. Waage,et al.  ASSOCIATION BETWEEN TUMOUR NECROSIS FACTOR IN SERUM AND FATAL OUTCOME IN PATIENTS WITH MENINGOCOCCAL DISEASE , 1987, The Lancet.

[40]  A. Sakurai,et al.  Relationship of hypoglycemia to tumor necrosis factor production and antitumor activity: role of glucose, insulin, and macrophages. , 1985, Journal of the National Cancer Institute.

[41]  A. Forrest,et al.  Letter: Procaine and malignant hyperthermia. , 1974, Lancet.

[42]  T. van der Poll,et al.  Tumor necrosis factor in sepsis: mediator of multiple organ failure or essential part of host defense? , 1995, Shock.

[43]  S. Calvano,et al.  Measurement of Inflammatory Mediators in Clinical Sepsis , 1995 .

[44]  L. Moldawer,et al.  Endogenous interleukin-10 protects against death in septic peritonitis in mice , 1994 .

[45]  H. Tilg,et al.  Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. , 1994, Blood.

[46]  T. van der Poll,et al.  Effects on leukocytes after injection of tumor necrosis factor into healthy humans. , 1992, Blood.

[47]  L. Tartaglia,et al.  Two TNF receptors. , 1992, Immunology today.

[48]  C. Dinarello,et al.  Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. , 1990, Blood.